BioCorRx Inc. (BICX) stock
BICXOTCServices-Specialty Outpatient Facilities, NECFiscal year ends December 31
$0.25+0.00 (0.00%)
Close on Oct 19, 2026Market cap $7.30MP/E –Yield –
BioCorRx r&d expenses
Research and development expenses are spending on new products and technology.
BioCorRx's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.37M, up 99.3% year over year. For fiscal 2025 it was $1.77M, up 19.3% from the year before. The highest annual figure on record is $4.27M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.77M | +19.3% |
| FY2024 | Dec 31, 2024 | $1.48M | +66.4% |
| FY2023 | Dec 31, 2023 | $891.06K | -38.9% |
| FY2022 | Dec 31, 2022 | $1.46M | -9.1% |
| FY2021 | Dec 31, 2021 | $1.61M | -62.4% |
| FY2020 | Dec 31, 2020 | $4.27M | +279.9% |
| FY2019 | Dec 31, 2019 | $1.13M | +641.3% |
| FY2018 | Dec 31, 2018 | $151.77K | -66.3% |
| FY2017 | Dec 31, 2017 | $450.72K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $712.38K | +140.0% |
| Q1 FY2026 | Mar 31, 2026 | $352.33K | +117.6% |
| Q4 FY2025 | Dec 31, 2025 | $305.52K | +12.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.00M | +118.3% |
| Q2 FY2025 | Jun 30, 2025 | $296.86K | -44.7% |
| Q1 FY2025 | Mar 31, 2025 | $161.92K | -24.3% |
| Q4 FY2024 | Dec 31, 2024 | $272.54K | +112.4% |
| Q3 FY2024 | Sep 30, 2024 | $460.14K | +60.3% |
| Q2 FY2024 | Jun 30, 2024 | $536.36K | +125.0% |
| Q1 FY2024 | Mar 31, 2024 | $213.83K | -9.9% |
| Q4 FY2023 | Dec 31, 2023 | $128.30K | -35.2% |
| Q3 FY2023 | Sep 30, 2023 | $286.96K | -59.8% |
| Q2 FY2023 | Jun 30, 2023 | $238.42K | -63.8% |
| Q1 FY2023 | Mar 31, 2023 | $237.39K | -74.4% |
| Q1 FY2022 | Mar 31, 2022 | $197.85K | -84.7% |
| Q2 FY2021 | Sep 30, 2021 | $713.25K | -47.0% |
| Q1 FY2021 | Mar 31, 2021 | $658.24K | -7.4% |
| Q4 FY2020 | Dec 31, 2020 | $928.85K | +70.2% |
| Q3 FY2020 | Sep 30, 2020 | $1.29M | +332.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.35M | +895.3% |
| Q1 FY2020 | Mar 31, 2020 | $710.57K | +386.8% |
| Q4 FY2019 | Dec 31, 2019 | $545.73K | +857.4% |
| Q3 FY2019 | Sep 30, 2019 | $298.26K | +734.1% |
| Q2 FY2019 | Jun 30, 2019 | $135.14K | – |
| Q1 FY2019 | Mar 31, 2019 | $145.97K | +147.4% |
| Q4 FY2018 | Dec 31, 2018 | $57.00K | -80.5% |
| Q3 FY2018 | Sep 30, 2018 | $35.76K | -66.7% |
| Q2 FY2018 | Jun 30, 2018 | $0 | -100.0% |
| Q1 FY2018 | Mar 31, 2018 | $59.01K | +616.9% |
| Q4 FY2017 | Dec 31, 2017 | $291.69K | – |
| Q3 FY2017 | Sep 30, 2017 | $107.46K | – |
| Q2 FY2017 | Jun 30, 2017 | $43.34K | – |
| Q1 FY2017 | Mar 31, 2017 | $8.23K | – |
| Q2 FY2016 | Jun 30, 2016 | $0 | – |
See a number that looks wrong?